Table 1.
Characteristics of DLBCL patients treated with R-CHOP
| Characteristic | No. of patients (%) | Age < 70 yr | Age ≥ 70 yr | p-value |
|---|---|---|---|---|
| Age | ||||
| No. (%) | 433 | 350 (80.8) | 83 (19.2) | |
| Median (range) | 58 (16-91) | 54 (16-69) | 74 (70-90) | |
| B Symptoms | ||||
| No | 327 (75.5) | 265 (75.7) | 62 (74.7) | 0.847 |
| Yes | 106 (24.5) | 85 (24.4) | 21 (25.3) | |
| Ann Arbor stage | ||||
| I/II | 233 (53.8) | 192 (54.9) | 41 (49.4) | 0.370 |
| III/IV | 200 (46.2) | 158 (45.1) | 42 (50.6) | |
| Performance status | ||||
| ECOG 0-1 | 357 (82.4) | 303 (86.6) | 54 (65.1) | < 0.001 |
| ECOG 2 or more | 76 (17.6) | 47 (13.4) | 29 (34.9) | |
| LDH level | ||||
| Normal | 179 (41.3) | 148 (42.5) | 31 (37.3) | 0.390 |
| Elevated | 252 (58.2) | 200 (57.5) | 52 (62.7) | |
| No. of extranodal sites | ||||
| 0-1 | 222 (51.3) | 181 (51.7) | 41 (49.4) | 0.704 |
| 2 or more | 211 (48.7) | 169 (48.3) | 42 (50.6) | |
| IPI score | ||||
| 0-1 | 208 (48.0) | 184 (52.6) | 24 (28.9) | < 0.001 |
| 2 | 105 (24.2) | 83 (23.7) | 22 (26.5) | |
| 3 | 71 (16.4) | 53 (15.1) | 18 (21.7) | |
| 4-5 | 49 (11.3) | 30 (8.6) | 19 (22.9) | |
| Bone marrow involvement | ||||
| Absence | 355 (82.0) | 295 (86.0) | 60 (76.9) | 0.046 |
| Presence | 66 (15.2) | 48 (14.0) | 18 (23.1) | |
| Bulky disease | ||||
| No | 340 (78.5) | 274 (78.3) | 66 (79.5) | 0.806 |
| Yes | 93 (21.5) | 76 (21.8) | 17 (20.5) |
DLBCL, diffuse large B cell lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index.